|
KEYNOTE-158: Final analysis of pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors. |
|
|
No Relationships to Disclose |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Research Funding - MSD (Inst) |
|
|
Consulting or Advisory Role - KYM Biosciences |
|
|
Employment - MSD (China) Co., Ltd. |
|
|
Employment - MSD (China) Co., Ltd. |
|
|
No Relationships to Disclose |
|
|
Employment - Merck Sharp & Dohme |
Stock and Other Ownership Interests - Merck |
|
|
Research Funding - MSD (Inst) |